New drug of artificial tears of hyaluronic acid derivative, Hilabak for dry eye treatment
Purpose: The clinical assessment of the therapeutic efficacy and tolerability of hyaluronic acid eye drops Hilabak. Methods: We had observed 40 patients diagnosed with dry eye (SG), 20 of them with mild SH (gr. I), 20 - moderate (gr. II). Apply eye drops Hilabak, 0.15% solution of hyaluronic acid, preservative-free, bottles with antimicrobial system ABAK. The instillation is 3-4 times per day. The duration of treatment is 28 days, the control of the eyes is on 1, 7, 14, 21, 28 days. Results: The subjective feelings disappeared or improved in the first days of the treatment. The Schirmer test indicators have risen from an average of 5.8±1.7 mm to 8.3±1.5 mm in group I and from 3.7±1.6 mm to 6.4±1.3 mm in Group II. A significant reduction in osmolarity tears from 327 to 286±0.6±1.7 in Group I and from 336 to 302±1.2±1.5 mOsms/L in Group II, i.e. to near normal levels. We’ve observed the early period of epithelialization of the cornea with the formation of the stable full epithelial cover, which was accompanied by an increase in visual acuity. The drug is well tolerated. Conclusion: The clinical observations have shown the high therapeutic efficacy of the eye drops Hilabak to treat dry eye diseases of varying etiology and severity and well tolerated for prolonged use 3-4 times a day.